| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Foley Todd | Director, 10%+ Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /sTodd Foley | 14 Jan 2026 | 0001473930 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AKTS | Common Stock | Conversion of derivative security | +597,391 | 597,391 | 12 Jan 2026 | See Footnote | F1, F2, F3, F4 | |||
| transaction | AKTS | Common Stock | Conversion of derivative security | +2,688,270 | +450% | 3,285,661 | 12 Jan 2026 | See Footnote | F2, F3, F5, F6 | ||
| transaction | AKTS | Common Stock | Conversion of derivative security | +716,872 | +22% | 4,002,533 | 12 Jan 2026 | See Footnote | F2, F3, F7, F8 | ||
| transaction | AKTS | Common Stock | Purchase | $4,191,660 | +232,870 | +5.8% | $18.00 | 4,235,403 | 12 Jan 2026 | See Footnote | F3, F9, F10 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AKTS | Series Seed Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -2,272,727 | -100% | $0.000000 | 0 | 12 Jan 2026 | Common Stock | 597,391 | See Footnote | F1, F2, F3 | |
| transaction | AKTS | Series A Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -10,227,273 | -100% | $0.000000 | 0 | 12 Jan 2026 | Common Stock | 2,688,270 | See Footnote | F2, F3, F5 | |
| transaction | AKTS | Series B Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -2,727,273 | -100% | $0.000000 | 0 | 12 Jan 2026 | Common Stock | 716,872 | See Footnote | F2, F3, F7 |
| Id | Content |
|---|---|
| F1 | The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC. |
| F2 | Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. |
| F3 | The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| F4 | The shares are held as follows: 556,810 by BV 2018, 29,593 by BV 2018(B) and 10,988 by AM BV2018. |
| F5 | The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018. |
| F6 | The shares are held as follows: 3,062,458 by BV 2018, 162,763 by BV 2018(B) and 60,440 by AM BV2018. |
| F7 | The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018. |
| F8 | The shares are held as follows: 3,730,631 by BV 2018, 198,275 by BV 2018(B) and 73,627 by AM BV2018. |
| F9 | The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B) and 4,284 by AM BV2018. |
| F10 | The shares are held as follows: 3,950,528 by BV 2018, 206,964 by BV 2018(B) and 77,911 by AM BV2018. |